CJC-1295 + Ipamorelin Research Guide: GHRH/GHRP Combo Mechanism
CJC-1295 without DAC pairs a GHRH analog with the selective GHRP Ipamorelin to study pulsatile growth-hormone release. Here is the research breakdown.
What is the CJC-1295 + Ipamorelin blend?
This blend combines CJC-1295 (without DAC) — a tetrasubstituted analog of growth-hormone-releasing hormone (GHRH) — with Ipamorelin, a pentapeptide GHRP that selectively activates the ghrelin receptor (GHS-R1a) on pituitary somatotropes.
The two peptides are studied together because they act on separate receptor systems that converge on the same downstream effect: pulsatile growth-hormone release from the anterior pituitary.
Mechanism of action
CJC-1295 binds the GHRH receptor, increasing cAMP and stimulating GH transcription and release. Ipamorelin activates the ghrelin receptor, amplifying GH release while remaining selective — i.e., without the cortisol, prolactin, or aldosterone elevations seen with older GHRPs like GHRP-6 or hexarelin.
In combination, the two peptides produce a larger and more physiologic pulse of GH than either alone in animal and ex vivo pituitary models.
Half-life
CJC-1295 without DAC has a half-life of roughly 30 minutes, consistent with the natural GHRH pulse window. Ipamorelin has a reported half-life of ~2 hours. The short windows are intentional — they preserve pulsatile (rather than tonic) GH release.
Compliance reminder
CJC-1295 + Ipamorelin is sold for laboratory research use only. Not for human consumption, diagnosis, treatment, or cure of any disease.
Frequently asked questions
What is the difference between CJC-1295 with and without DAC?
DAC (Drug Affinity Complex) extends CJC-1295's half-life from hours to roughly 8 days by binding to serum albumin. The 'no-DAC' version (used in this blend) preserves natural pulsatile GH release.